Pre-made Begelomab benchmark antibody ( Whole mAb, anti-DPP4/DPP-4 therapeutic antibody, Anti-ADABP/ADCP2/CD26/DPPIV/TP103 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Begelomab biosimilar, Whole mAb, Anti-DPP4/DPP-4 Antibody: Anti-ADABP/ADCP2/CD26/DPPIV/TP103 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

A monoclonal antibody against the human dipeptidyl peptidase 4 (dipeptidylpeptidase IV, DPPIV, DPP4; CD26), with potential activity against graft-versus-host disease (GvHD). Upon administration, begelomab binds to CD26 expressed on T-cells. This inhibits the stimulation of T-cells and may prevent GvHD.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-054-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Begelomab biosimilar, Whole mAb, Anti-DPP4/DPP-4 Antibody: Anti-ADABP/ADCP2/CD26/DPPIV/TP103 therapeutic antibody
INN Name	Begelomab
Target	DPP-4
Format	Whole mAb
Derivation	Mouse
Species Reactivity	Human
CH1 Isotype	IgG2b
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II/III
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2014
Year Recommended	2015
Companies	ADIENNE
Conditions Approved	na
Conditions Active	Graft-versus-host disease
Conditions Discontinued	na
Development Tech	na